摘要
目的 探讨前列地尔联合厄贝沙坦片对糖尿病患者肾功能以及尿蛋白水平的影响.方法 将54例糖尿病肾病患者随机分为厄贝沙坦组20例和联合用药组34例.厄贝沙坦组患者仅给予厄贝沙坦,联合用药组给予厄贝沙坦联合前列地尔.观察两组患者治疗前、治疗后24 h尿蛋白、血肌酐和血尿素氮、血管内皮素、糖化血红蛋白和血脂水平,比较两组临床疗效.结果 厄贝沙坦组临床总有效率为60.00%,联合用药组临床总有效率为94.12%,差异有统计学意义（P＜0.05）.治疗后,两组24 h尿蛋白、血肌酐、血尿素氮、血管内皮素、糖化血红蛋白和血脂水平降低,且联合用药组显著低于厄贝沙坦组,差异均有统计学意义（P＜0.05）.结论 相较于单独使用厄贝沙坦,前列地尔联合厄贝沙坦片治疗糖尿病肾病能更快的降低患者的尿蛋白水平,改善肾功能.
Objective To investigate the effects of combined application of alprostadil and irbesartan tablets on renal function and urinary protein level in 24 h of patients with diabetes nephropathy. Methods Fifty-four cases of patients with diabetes nephropathy were randomly divided into irbesartan group （n=20） and combined treatment group （n=34）. Patients in irbesartan group were only given irbesartan, while patients in combined treatment group were given irbesartan combined with alprostadil. The 24 h urinary protein, serum creatinine and blood urea nitrogen, blood endothelin, glycosylated hemoglobin and serum lipid levels, and the curative effect of two groups before and after treatment were compared. Results The clinical efficiency of the irbesartan group was 60.00%, the clinical efficiency of the combined treatment group was 94.12%, and the difference was statistically significant （P〈0.05）. After treatment, 24 h urine protein, serum creatinine, blood urea nitrogen, blood vessels, endothelin glyeosylated hemoglobin and blood lipid levels of two groups were significant lower than before treatment （P〈0.05）; after treatment, the 24 h urine protein, serum creatinine, blood urea nitrogen, blood vessels, endothelin, glycosylated hemoglobin and blood lipid levels of the combined treatment group were lower than those of the irbesartan group （P〈0.05）. Conclusion Compared to the using of irbesartan alone, the combined application of alprostadil and irbesartan tablets for the treatment of diabetic nephropathy can reduce proteinuria and improve renal function faster.
出处
《临床研究》
2017年第6期27-28,共2页
Clinical Research
